Healthcare / Pharmaceutical RetailersJakartaID
$750.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-126.3B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.60T
P/E
N/A
•EV/EBITDA
N/A
•ROE
2.8%
↑Gross Margin
59.8%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+167.1%
FCF CAGR
—
FCF margin
22.8%
FCF / Net income
8.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $201.47B · net income $5.24B · FCF $45.84B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $201.47B | $201.47B | $191.99B | $175.13B | $175.09B | $181.84B | $1.48B |
| Net Income | $5.24B | $5.24B | $1.21B | $16.51B | $23.67B | $25.04B | $352.9M |
| EBITDA | — | — | — | — | — | $33.58B | — |
| EPS | 1.09 | 1.09 | 0.25 | 3.44 | 9.86 | 5.22 | 0.15 |
| Gross Margin | 59.8% | 59.8% | 58.0% | 59.9% | 52.2% | 37.2% | 32.5% |
| Operating Margin | 18.0% | 18.0% | 12.5% | 16.3% | 18.3% | 18.2% | 24.4% |
| Net Margin | 2.6% | 2.6% | 0.6% | 9.4% | 13.5% | 13.8% | 23.8% |
| Balance Sheet | |||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Current Ratio | 1.37 | 1.37 | 1.38 | 2.08 | 5.56 | 6.21 | 1.71 |
| Cash Flow | |||||||
| Free Cash Flow | $45.84B | $45.84B | $-126.28B | $-134.50B | $-43.69B | $1.23B | $-631.9M |
| Returns | |||||||
| ROE | 2.8% | 2.8% | 0.7% | 9.2% | 14.5% | 94.9% | 26.1% |
| Valuation | |||||||
| P/E | — | — | — | — | — | 5.22 | — |
| EV/EBITDA | — | — | — | — | — | 107.17 | — |
| P/B | — | — | — | — | — | 136.38 | — |
| Growth & Yield | |||||||
| Revenue Growth | 4.9% | 4.9% | 9.6% | 0.0% | -3.7% | 12163.3% | — |
| EPS Growth | 334.0% | 334.0% | -92.7% | -65.1% | -5.5% | 6997.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
293.6%
EPS terminal req.
$66.55
Spread vs growth
40.4%
5Y implied EPS CAGR
136.4%
EPS terminal req.
$80.53
Spread vs growth
197.6%
10Y implied EPS CAGR
61.2%
EPS terminal req.
$129.69
Spread vs growth
272.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+867.7%
Start / end P/E
308.2x → 687.3x
EPS bridge
0.25 → 1.09
Residual
+410.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.